VEXAS综合征患者成功接受异基因造血干细胞移植:两中心经验
本文回顾性报告6例接受异基因造血干细胞移植的VEXAS综合征患者,其中4例因难治性危及生命的自身炎症症状而移植。3例移植后32、38、37个月持续完全缓解,2例移植后3和5个月完全缓解,1例移植后死亡。提示移植可能治愈重症VEXAS,但需临床试验明确获益亚组。
要点
- VEXAS综合征由UBA1体细胞突变引起,表现为晚发难治性自身炎症和血液学异常。
- 6例接受异基因造血干细胞移植,5例获完全缓解,1例移植后死亡。
- 移植可能为重症VEXAS的治愈选项,但需临床试验明确适用人群。
核心结论
- 异基因造血干细胞移植可能治愈伴有严重表现的VEXAS综合征患者。
研究设计与样本
- 回顾性研究,两中心共纳入6例接受异基因造血干细胞移植的VEXAS综合征患者。
主要发现
- 4例移植由多种治疗难治的危及生命自身炎症症状驱动。
- 3例移植后32、38、37个月持续完全缓解。
- 2例移植后3和5个月完全缓解。
- 1例移植后死亡。
关键数值与推荐
- VEXAS综合征由UBA1体细胞突变导致,表现为晚发自身炎症症状和血液学异常。
- 目前尚无经证实的治疗指南。
临床怎么用
- 对伴有严重难治性表现的VEXAS综合征患者,可考虑异基因造血干细胞移植作为潜在治愈手段。
- 需权衡移植并发症与副作用,并考虑其他潜在治疗选择。
局限性
- 回顾性研究,样本量小(6例)。
- 需临床试验确定可从移植获益的患者亚组及其在治疗策略中的位置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recently described vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is caused by somatic mutations in UBA1. Patients with VEXAS syndrome display late-onset autoinflammatory symptoms, usually refractory to treatment, and hematologic abnormalities. The identification of an easily-accessible specific marker (UBA1 mutations) is of particular interest as it allows the convergence of various inflammatory and hematological symptoms in a unique clinico-biological entity and gives the opportunity to design specific treatment strategies. Here we retrospectively identified 6 patients with VEXAS syndrome who underwent allogeneic hematopoietic stem cell transplantation (ASCT). To date, no treatment guidelines have been validated. In 4 patients, ASCT was guided by life-threatening autoinflammatory symptoms that were refractory to multiple therapies. Three patients are in durable complete remission 32, 38, and 37 months after ASCT. Two others are in complete remission response after 3 and 5 months. One unfortunately died post-ASCT. This report suggests that ASCT could be a curative option in patients with VEXAS syndrome and severe manifestations. Considering the complications and side effects of the procedure as well as the existence of other potential treatment, clinical trials are needed to define the subgroup of patients who will benefit from this strategy and its place in the therapeutic arsenal against VEXAS syndrome.
引用
- Diarra A, Duployez N, Fournier E, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022. PMID: 34714914. doi:10.1182/bloodadvances.2021004749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。